Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer

Scientists suggested that DNA methylation pathway is deregulated after enzalutamide resistance onset and that targeting DNA methyltransferases restored the sensitivity to enzalutamide in prostate cancer cells.